- Molecular NameEmtricitabine
- Synonymemtricitabine
- Weight229.211
- Drugbank_IDDB00879
- ACS_NO143491-57-0
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-0.96
- pkaN/A
- LogD (pH=7, predicted)-0.96
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.37
- LogSw (predicted, AB/LogsW2.0)22.47
- Sw (mg/ml) (predicted, ACD/Labs)9.85
- No.of HBond Donors3
- No.of HBond Acceptors6
- No.of Rotatable Bonds2
- TPSA88.15
- StatusFDA approved
- AdministrationN/A
- PharmacologyA nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection in adults and children.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability93.0
- Protein binding4.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic oxidation and glucuronidation CYP system not involved
- Half life10 h
- ExcretionRenal (86%) and fecal (14%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityIn clinical practice, toxicity with emtricitabine is unusual. The most common treatment-related adverse events are diarrhea, headache, nausea, and rash. These symptoms are generally mild to moderate in severity, but they caused 1% of clinical trial patients to give up treatment. Skin discoloration, which is typically reported as hyperpigmentation and usually affects either the palms of the hands or the soles of the feet, is reported in less than 2% of individuals and is almost exclusive to patients of African origin. Among the more severe side effects patients may experience are a hepatotoxicity or a lactic acidosis.
- LD50 (rat)N/A
- LD50 (mouse)N/A